

Mandana Nikpour

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5547131/mandana-nikpour-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

1,607
citations

22
h-index

38
g-index

82
ext. papers

2,218
ext. citations

4.5
avg, IF

4.61
L-index

#	Paper	IF	Citations
74	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1615-21	2.4	235
73	Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. <i>Arthritis Research and Therapy</i> , 2011 , 13, R211	5.7	108
72	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1152-8		90
71	Epidemiology of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 857-69	5.3	76
70	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 329-54, vii-viii	2.4	75
69	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5.7	63
68	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R156	5.7	61
67	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 62	5.7	59
66	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000157	4.6	53
65	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019 , 10, 4955	17.4	46
64	Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 131-7	5.3	41
63	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. <i>Arthritis Research and Therapy</i> , 2017 , 19, 42	5.7	37
62	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R193	5.7	37
61	The need to define treatment goals for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 567-71	8.1	33
60	Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2017 , 19, 122	5.7	33
59	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009 , 11, 248-54	4.9	32
58	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. <i>Arthritis Research and Therapy</i> , 2016 , 18, 260	5.7	29

57	Musculoskeletal Manifestations of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 507-18	2.4	29
56	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , 2019 , 1, e95-e102	14.2	26
55	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 288-94	4.1	26
54	Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 134	3.5	25
53	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
52	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 29909	4.9	22
51	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S131-5	2.2	22
50	Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 221-239	5.3	21
49	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
48	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R125	5.7	20
47	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 807-816	2.4	16
46	Defining primary systemic sclerosis heart involvement: A scoping literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 874-887	5.3	16
45	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 425-433	2.3	14
44	Measures of disease status in systemic sclerosis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 473-487	5.3	13
43	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3052-3		13
42	CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. <i>Journal of Autoimmunity</i> , 2018 , 88, 131-138	15.5	13
41	Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. <i>Arthritis Research and Therapy</i> , 2019 , 21, 299	5.7	12
40	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1289-1295	4.7	12

39	Hydroxychloroquine in dermatology: New perspectives on an old drug. <i>Australasian Journal of Dermatology</i> , 2020 , 61, e150-e157	1.3	11
38	Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 170-176	2.2	11
37	The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 246	5.7	10
36	A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1728-1750	2.3	10
35	Using discrete choice experiments as a decision aid in total knee arthroplasty: study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 416	2.8	9
34	Systemic sclerosis: The need for structured care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 3-21	5.3	9
33	The role of inflammatory markers in assessment of disease activity in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 126-134	2.2	9
32	Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. <i>Arthritis Care and Research</i> , 2021 , 73, 732-741	4.7	8
31	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
30	Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72, 1625-1635	4.7	7
29	Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 79-84	2.2	7
28	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	6
27	Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 299-309	5.3	6
26	Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 188-195	2.3	4
25	Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 2006-14	4.1	4
24	The clinical and economic burden of systemic sclerosis related interstitial lung disease. <i>Rheumatology</i> , 2020 , 59, 1878-1888	3.9	4
23	Correspondence regarding research letter to the editor by Mathian , Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquineS <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
22	Cancer and scleroderma: recent insights. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 479-487	5.3	3

21	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 495-512	5.3	3
20	Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome? Sby Coudrec. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e138	2.4	3
19	How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e119	2.4	2
18	How do surgeons trade-off between patient outcomes and risk of complications in total knee arthroplasty? a discrete choice experiment in Australia. <i>BMJ Open</i> , 2019 , 9, e029406	3	2
17	The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. <i>BMC Pulmonary Medicine</i> , 2019 , 19, 226	3.5	2
16	Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 130-137	2.2	2
15	Screening for pulmonary arterial hypertension in systemic sclerosis: Now or never!. <i>European Journal of Rheumatology</i> , 2020 , 7, S187-S192	1.7	1
14	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021 , 160, 2158-2162	5.3	1
13	Response to: Differentiating disease activity from damage in systemic sclerosis: it's still early days! S by Jain and Sharma. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e99	2.4	1
12	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021 , 60, 5185-5193	3.9	1
11	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
10	Not at target prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 70	5.7	1
9	Safety of Intra-articular Corticosteroid Injection. <i>Radiology</i> , 2020 , 294, 720-722	20.5	0
8	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151973	5.3	0
7	Performance of the 2017 EUSTAR activity index in an scleroderma cohort. <i>Clinical Rheumatology</i> , 2020 , 39, 3701-3705	3.9	0
6	Response to: Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter Sby Sbeih. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e149	2.4	0
5	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 142-148	2.2	0
4	Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 103	5.7	0

- 3 Response to: Physician global assessment in systemic lupus erythematosus: can we rely on its reliability? Sby Chessa. *Annals of the Rheumatic Diseases*, **2020**, 2.4
- 2 The assessment of disease activity in rheumatic diseases. *International Journal of Rheumatology*, **2013**, 2013, 275691 2
- 1 Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 131, 142-148 2.2